Paladin,

Thanks for the reminder to add potential US listing to the list. That one may be the first to occur. Original list revised:

US listing for Common Shares (note, the shareholder approval for potential consolidation was only approved for the 12 month period ending Sept 12, 2019). See here for details.

NDA and MAA filings with FDA and EMA, respectively

Decisions by FDA/EMA to grant priority or standard review

Need or no need for FDA Advisory Committee meeting

NDA and MAA approvals

Specifics about what the NDA/MAA label includes or doesn't include

Details of funding and timeline for already planned/announced trials: Fabry, Pulmonary Arterial Hypertension, Renal and Vascular Cognitive Dementia Trials

Details of other potential follow up trial(s) for cardiovascular, renal and cognitive diseases to expand label & patient population beyond the low-HDL, T2D with recent ACS patients in BETonMACE